ATRC:NSD-AtriCure, Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 57.20

Change

+0.84 (+1.49)%

Market Cap

USD 2.54B

Volume

0.34M

Average Target Price

USD 58.00 (+1.40%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-20 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical, Inc

+20.16 (+2.59%)

USD91.51B 88.68 67.18
ALC Alcon Inc.

+8.59 (+13.24%)

USD31.61B N/A N/A
HOLX Hologic, Inc

+1.23 (+1.62%)

USD19.53B 18.05 15.48
NVCR NovoCure Limited

+4.10 (+2.44%)

USD17.13B 914.57 503.82
MASI Masimo Corporation

+2.53 (+0.97%)

USD14.37B 67.79 47.43
XRAY DENTSPLY SIRONA Inc

+0.36 (+0.62%)

USD12.75B 126.19 43.33
RGEN Repligen Corporation

-5.52 (-2.48%)

USD12.16B 269.32 118.05
IRTC iRhythm Technologies, Inc

+10.85 (+4.21%)

USD7.44B N/A N/A
ICUI ICU Medical, Inc

+0.25 (+0.11%)

USD4.56B 57.55 23.70
STAA STAAR Surgical Company

-0.63 (-0.70%)

USD4.13B 473.44 483.29

ETFs Containing ATRC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.75% 34% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.75% 34% F 35% F
Trailing 12 Months  
Capital Gain 49.82% 63% D 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.82% 63% D 73% C
Trailing 5 Years  
Capital Gain 205.07% 62% D- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 205.07% 62% D- 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 29.52% 45% F 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.52% 45% F 82% B-
Risk Return Profile  
Volatility (Standard Deviation) 28.34% 77% C+ 51% F
Risk Adjusted Return 104.16% 84% B 93% A
Market Capitalization 2.54B 66% D 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.00 45% F 28% F
Price / Cash Flow Ratio -160.49 97% A+ 97% A+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -13.52% 35% F 39% F
Return on Invested Capital -11.13% 35% F 33% F
Return on Assets -4.38% 32% F 34% F
Debt to Equity Ratio 24.11% 62% D- 60% D-
Technical Ratios  
Short Ratio 5.52 35% F 23% F
Short Percent 6.01% 32% F 34% F
Beta 1.13 53% F 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector